Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen
Public ClinicalTrials.gov record NCT00051844. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double Blind- Randomized, Placebo-controlled Study of Two Doses of Capravirine (AG1549) in Combination With Viracept and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Infected Patients Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a 48 week study that is intended for HIV Infected persons whose first treatment regimen was with a nonnucleoside reverse transcriptase inhibitor (NNRTI) and who are now failing that regimen. They must be currently on their failing regimen to be eligible.
Study identification
- NCT ID
- NCT00051844
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 179 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2002 (Type not available)
- Primary completion
- Not listed
- Completion
- Nov 2004 (Actual)
- Last update posted
- May 10, 2011
2002 – 2004
United States locations
- U.S. sites
- 30
- U.S. states
- 12
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Beverly Hills | California | 90211 | — |
| Pfizer Investigational Site | Long Beach | California | 90813 | — |
| Pfizer Investigational Site | Newport Beach | California | 92663 | — |
| Pfizer Investigational Site | San Francisco | California | 94115 | — |
| Pfizer Investigational Site | San Francisco | California | 94121 | — |
| Pfizer Investigational Site | West Hollywood | California | 90069 | — |
| Pfizer Investigational Site | Fort Lauderdale | Florida | 33311 | — |
| Pfizer Investigational Site | Miami | Florida | 33137 | — |
| Pfizer Investigational Site | Safety Harbor | Florida | 34695 | — |
| Pfizer Investigational Site | Tampa | Florida | 33602 | — |
| Pfizer Investigational Site | Atlanta | Georgia | 30339-3915 | — |
| Pfizer Investigational Site | Jonesboro | Georgia | 30236 | — |
| Pfizer Investigational Site | Tucker | Georgia | 30084 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60611 | — |
| Pfizer Investigational Site | Wichita | Kansas | 67214 | — |
| Pfizer Investigational Site | Jackson | Mississippi | 39202 | — |
| Pfizer Investigational Site | Brooklyn | New York | 11203 | — |
| Pfizer Investigational Site | New York | New York | 10003 | — |
| Pfizer Investigational Site | Stony Brook | New York | 11794 | — |
| Pfizer Investigational Site | Huntersville | North Carolina | 28078 | — |
| Pfizer Investigational Site | Winston-Salem | North Carolina | 27157-1042 | — |
| Pfizer Investigational Site | Akron | Ohio | 44304 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45267 | — |
| Pfizer Investigational Site | Portland | Oregon | 97209 | — |
| Pfizer Investigational Site | Portland | Oregon | 97210 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19107 | — |
| Pfizer Investigational Site | Austin | Texas | 78705 | — |
| Pfizer Investigational Site | Dallas | Texas | 75246 | — |
| Pfizer Investigational Site | Galveston | Texas | 77555 | — |
| Pfizer Investigational Site | Houston | Texas | 77009 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00051844, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 10, 2011 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00051844 live on ClinicalTrials.gov.